Arch Therapeutics, Inc. (ARTH)
USD 0.16
(-10.93%)
USD 0.16
(-10.93%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2439.00 USD | 93.19% |
| 2022 | -35.83 Thousand USD | -143.51% |
| 2021 | -14.71 Thousand USD | -112.49% |
| 2020 | -6926.00 USD | 15.93% |
| 2019 | -8238.00 USD | -54.21% |
| 2018 | -5342.00 USD | -256.61% |
| 2017 | -1498.00 USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 22.26 Thousand USD | 37.11% |
| 2024 Q2 | 10.31 Thousand USD | -53.68% |
| 2024 Q3 | 9834.00 USD | -4.63% |
| 2023 Q1 | -11.37 Thousand USD | -889.86% |
| 2023 Q2 | -2064.00 USD | 81.85% |
| 2023 FY | -2439.00 USD | 93.19% |
| 2023 Q3 | -5236.00 USD | -153.68% |
| 2023 Q4 | 16.23 Thousand USD | 410.08% |
| 2022 Q2 | -14.3 Thousand USD | -18.22% |
| 2022 FY | -35.83 Thousand USD | -143.51% |
| 2022 Q4 | 1440.00 USD | 113.24% |
| 2022 Q1 | -12.09 Thousand USD | 17.24% |
| 2022 Q3 | -10.87 Thousand USD | 23.92% |
| 2021 Q1 | -372.00 USD | 0.0% |
| 2021 Q4 | -14.61 Thousand USD | -1729.16% |
| 2021 FY | -14.71 Thousand USD | -112.49% |
| 2021 Q2 | -102.00 USD | 72.58% |
| 2021 Q3 | -799.00 USD | -683.33% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | -6926.00 USD | 15.93% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | -8238.00 USD | -54.21% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | -5342.00 USD | -256.61% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | -1498.00 USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.021% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 99.237% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.002% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.991% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 94.946% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 98.037% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.016% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 178.627% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.025% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 103.711% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 92.858% |
| Mesoblast Limited | -35.16 Million USD | 99.993% |
| Marizyme, Inc. | 457.7 Thousand USD | 100.533% |
| Genus plc | 178.7 Million USD | 100.001% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.001% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 103.92% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 100.595% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 77.827% |
| ContraFect Corporation | -154 Thousand USD | 98.416% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 95.122% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 103.177% |
| IMV Inc. | -962.29 Thousand USD | 99.747% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 99.371% |
| MultiCell Technologies, Inc. | 49.32 USD | 5045.255% |
| ONE Bio Corp. | 20.12 Million USD | 100.012% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.006% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 104.988% |
| Q BioMed Inc. | -8988.00 USD | 72.864% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.009% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 84.187% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.005% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 99.786% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 103.484% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 50.747% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 101.736% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 97.499% |
| GB Sciences, Inc. | -624.00 USD | -290.865% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 97.165% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -1072.596% |
| Enzolytics Inc. | 30.7 Thousand USD | 107.943% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 100.506% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 99.526% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 100.395% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.001% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 72.459% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 97.091% |
| Kadimastem Ltd | -630.13 Thousand USD | 99.613% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 100.247% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.025% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.016% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 79.392% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 101.381% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 101.381% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 100.18% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 91.59% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 100.542% |
| SYBLEU INC | 11.69 Thousand USD | 120.853% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.053% |
| Bioxytran, Inc. | -8285.00 USD | 70.561% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 99.346% |
| Neutra Corp. | 14.33 Thousand USD | 117.014% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 97.026% |
| PureTech Health plc | -1.6 Million USD | 99.848% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 99.756% |
| IXICO plc | 3.27 Million USD | 100.075% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 99.649% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 99.864% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 113.55% |